Therapeutic method for cat with chronic kidney disease
A therapeutic method for a cat treats chronic kidney disease to inhibit progression of chronic kidney disease into IRIS stage 4 or kidney death of a cat or improve the overall survival rate or the observed survival rate. The therapeutic method for a cat with chronic kidney disease inhibits progression of chronic kidney disease into IRIS stage 4 or kidney death of a cat by administering a therapeutic agent comprising, as an active ingredient, a compound represented by the formula (I) to a cat with stage 3 or 4 chronic kidney disease defined by the staging system established by the International Renal Interest Society (the IRIS staging) in an amount of 90 to 130 μg of the compound represented by formula (I) daily: wherein R represents hydrogen or a pharmacologically acceptable cation.
1. A therapeutic method for a cat with chronic kidney disease to inhibit kidney death of a cat with chronic kidney disease by administering a therapeutic agent comprising, as an active ingredient, a compound represented by the formula (I) to a cat with stage 4 chronic kidney disease defined by the staging system established by the International Renal Interest Society (the IRIS staging) in an amount of 90 to 130 μg of the compound represented by the formula (I) daily:
wherein R represents hydrogen or a pharmacologically acceptable cation.
2. A therapeutic method for a cat with chronic kidney disease to improve the overall survival rate or the observed survival rate of a cat with chronic kidney disease by administering a therapeutic agent comprising, as an active ingredient, a compound represented by the formula (I) to a cat with stage 4 chronic kidney disease defined by the staging system established by the International Renal Interest Society (the IRIS staging) in an amount of 90 to 130 μg of the compound represented by the formula (I) daily:
wherein R represents hydrogen or a pharmacologically acceptable cation.
3. A therapeutic method for a cat with chronic kidney disease to improve the overall survival rate or the observed survival rate of a cat with chronic kidney disease by administering a therapeutic agent comprising, as an active ingredient, a compound represented by the formula (I) to a cat with stage 3 chronic kidney disease defined by the staging system established by the International Renal Interest Society (the IRIS staging) in an amount of 90 to 130 μg of the compound represented by the formula (I) daily:
wherein R represents hydrogen or a pharmacologically acceptable cation.
4. A therapeutic method for a cat with chronic kidney disease to improve the overall survival rate or the observed survival rate of a cat with chronic kidney disease by administering a therapeutic agent comprising, as an active ingredient, a compound represented by the formula (I) to a cat with stage 3 chronic kidney disease defined by the staging system established by the International Renal Interest Society (the IRIS staging) having also complications/comorbidities selected from chronic heart failure, diabetes mellitus, pancreatitis, neoplasia, hyperthyroidism, hypertension, proteinuria, hypokalemia, hyperphosphatemia, or anemia in an amount of 90 to 130 μg of the compound represented by the formula (I) daily:
wherein R represents hydrogen or a pharmacologically acceptable cation.
5. A therapeutic method for a cat with chronic kidney disease to improve the overall survival rate or the observed survival rate of a cat with chronic kidney disease by administering a therapeutic agent comprising, as an active ingredient, a compound represented by the formula (I) to a cat with stage 3 or 4 chronic kidney disease defined by the staging system established by the International Renal Interest Society (the IRIS staging) exhibiting body weight loss to less than 4.2 kg in an amount of 90 to 130 μg of the compound represented by the formula (I) daily:
wherein R represents hydrogen or a pharmacologically acceptable cation.
6. The therapeutic method according to claim 1 , wherein the compound represented by the formula (I) is beraprost sodium.
7. The therapeutic method according to claim 2 , wherein the compound represented by the formula (I) is beraprost sodium.
8. The therapeutic method according to claim 3 , wherein the compound represented by the formula (I) is beraprost sodium.
9. The therapeutic method according to claim 4 , wherein the compound represented by the formula (I) is beraprost sodium.
10. The therapeutic method according to claim 5 , wherein the compound represented by the formula (I) is beraprost sodium.
11. The therapeutic method according to claim 1 , wherein the cat having chronic kidney disease with IRIS stage 4 exhibits body weight loss to less than 4.2 kg.
12. The therapeutic method according to claim 2 , wherein the cat having chronic kidney disease with IRIS stage 4 exhibits body weight loss to less than 4.2 kg.
13. The therapeutic method according to claim 3 , wherein the cat having chronic kidney disease with IRIS stage 3 exhibits body weight loss to less than 4.2 kg.
14. The therapeutic method according to claim 4 , wherein the cat having chronic kidney disease with IRIS stage 3 exhibits body weight loss to less than 4.2 kg.
15. The therapeutic method according to claim 3 , wherein the cat having chronic kidney disease with IRIS stage 3 exhibits serum creatinine of 2.9 mg/dL to 5.0 mg/dL and serum SDMA of 9.0 μg/dL or higher.
16. The therapeutic method according to claim 4 , wherein the cat having chronic kidney disease with IRIS stage 3 exhibits serum creatinine of 2.9 mg/dL to 5.0 mg/dL and serum SDMA of 9.0 μg/dL or higher.
17. The therapeutic method according to claim 5 , wherein the cat having chronic kidney disease with IRIS stage 3 exhibits serum creatinine of 2.9 mg/dl to 5.0 mg/dL and serum SDMA of 9.0 μg/dL or higher.
18. The therapeutic method according to claim 1 , wherein the cat having chronic kidney disease with IRIS stage 4 exhibits serum creatinine of higher than 5.0 mg/dl and serum SDMA of 9.0 μg/dL or higher.
19. The therapeutic method according to claim 2 , wherein the cat having chronic kidney disease with IRIS stage 4 exhibits serum creatinine of higher than 5.0 mg/dL and serum SDMA of 9.0 μg/dL or higher.
20. The therapeutic method according to claim 5 , wherein the cat having chronic kidney disease with IRIS stage 4 exhibits serum creatinine of higher than 5.0 mg/dL and serum SDMA of 9.0 μg/dL or higher.
21. The therapeutic method according to claim 5 , wherein the therapeutic agent is administered to the cat having chronic kidney disease with IRIS stage 3.
22. The therapeutic method according to claim 1 , wherein the cat having chronic kidney disease with IRIS stage 4 satisfies the serum creatinine criterion of the IRIS staging criteria.
23. The therapeutic method according to claim 2 , wherein the cat having chronic kidney disease with IRIS stage 4 satisfies the serum creatinine criterion of the IRIS staging criteria.
24. The therapeutic method according to claim 3 , wherein the cat having chronic kidney disease with IRIS stage 3 satisfies the serum creatinine criterion of the IRIS staging criteria.
25. The therapeutic method according to claim 4 , wherein the cat having chronic kidney disease with IRIS stage 3 satisfies the serum creatinine criterion of the IRIS staging criteria.
26. The therapeutic method according to claim 5 , wherein the cat having chronic kidney disease with IRIS stage 3 or 4 satisfies the serum creatinine criterion of the IRIS staging criteria.
27. The therapeutic method according to claim 1 , wherein the compound represented by the formula (I) is administered to the cat with chronic kidney disease in an amount of 14.1 to 52.4 μg/kg body weight/day.
28. The therapeutic method according to claim 2 , wherein the compound represented by the formula (I) is administered to the cat with chronic kidney disease in an amount of 14.1 to 52.4 μg/kg body weight/day.
29. The therapeutic method according to claim 3 , wherein the compound represented by the formula (I) is administered to the cat with chronic kidney disease in an amount of 14.1 to 52.4 μg/kg body weight/day.
30. The therapeutic method according to claim 4 , wherein the compound represented by the formula (I) is administered to the cat with chronic kidney disease in an amount of 14.1 to 52.4 μg/kg body weight/day.
31. The therapeutic method according to claim 5 , wherein the compound represented by the formula (I) is administered to the cat with chronic kidney disease in an amount of 14.1 to 52.4 μg/kg body weight/day.
32. The therapeutic method according to claim 1 , wherein administration to the cat with chronic kidney disease is performed twice daily.
33. The therapeutic method according to claim 2 , wherein administration to the cat with chronic kidney disease is performed twice daily.
34. The therapeutic method according to claim 3 , wherein administration to the cat with chronic kidney disease is performed twice daily.
35. The therapeutic method according to claim 4 , wherein administration to the cat with chronic kidney disease is performed twice daily.
36. The therapeutic method according to claim 5 , wherein administration to the cat with chronic kidney disease is performed twice daily.
37. The therapeutic method according to claim 1 , wherein administration to the cat with chronic kidney disease is performed during or after feeding.
38. The therapeutic method according to claim 2 , wherein administration to the cat with chronic kidney disease is performed during or after feeding.
39. The therapeutic method according to claim 3 , wherein administration to the cat with chronic kidney disease is performed during or after feeding.
40. The therapeutic method according to claim 4 , wherein administration to the cat with chronic kidney disease is performed during or after feeding.
41. The therapeutic method according to claim 5 , wherein administration to the cat with chronic kidney disease is performed during or after feeding.
42. The therapeutic method according to claim 1 , wherein administration to the cat with chronic kidney disease is performed in addition to a standard care for feline chronic kidney disease.
43. The therapeutic method according to claim 2 , wherein administration to the cat with chronic kidney disease is performed in addition to a standard care for feline chronic kidney disease.
44. The therapeutic method according to claim 3 , wherein administration to the cat with chronic kidney disease is performed in addition to a standard care for feline chronic kidney disease.
45. The therapeutic method according to claim 4 , wherein administration to the cat with chronic kidney disease is performed in addition to a standard care for feline chronic kidney disease.
46. The therapeutic method according to claim 5 , wherein administration to the cat with chronic kidney disease is performed in addition to a standard care for feline chronic kidney disease.
47. The therapeutic method according to claim 42 , wherein the standard care is a therapeutic method defined by the guidelines from the International Society of Feline Medicine or the International Renal Interest Society.
48. The therapeutic method according to claim 43 , wherein the standard care is a therapeutic method defined by the guidelines from the International Society of Feline Medicine or the International Renal Interest Society.
49. The therapeutic method according to claim 44 , wherein the standard care is a therapeutic method defined by the guidelines from the International Society of Feline Medicine or the International Renal Interest Society.
50. The therapeutic method according to claim 45 , wherein the standard care is a therapeutic method defined by the guidelines from the International Society of Feline Medicine or the International Renal Interest Society.
51. The therapeutic method according to claim 46 , wherein the standard care is a therapeutic method defined by the guidelines from the International Society of Feline Medicine or the International Renal Interest Society.
52. The therapeutic method according to claim 1 , wherein the cat with chronic kidney disease also has chronic heart failure, diabetes mellitus, pancreatitis, neoplasia, hyperthyroidism, hypertension, proteinuria, hypokalemia, hyperphosphatemia, or anemia.
53. The therapeutic method according to claim 2 , wherein the cat with chronic kidney disease also has chronic heart failure, diabetes mellitus, pancreatitis, neoplasia, hyperthyroidism, hypertension, proteinuria, hypokalemia, hyperphosphatemia, or anemia.
54. The therapeutic method according to claim 3 , wherein the cat with chronic kidney disease also has chronic heart failure, diabetes mellitus, pancreatitis, neoplasia, hyperthyroidism, hypertension, proteinuria, hypokalemia, hyperphosphatemia, or anemia.
55. The therapeutic method according to claim 5 , wherein the cat with chronic kidney disease also has chronic heart failure, diabetes mellitus, pancreatitis, neoplasia, hyperthyroidism, hypertension, proteinuria, hypokalemia, hyperphosphatemia, or anemia.